Chinese biotech company Jacobio Pharma announced on Monday that it had received approval from Chinese regulatory authorities for the registration phase-3 clinical trial of a combination therapy using its SHP2 inhibitor drug candidate JAB-3312. SHP2 inhibitors are expected worldwide to have a substantial clinical effect in cancer and immunity disease treatment, and the approval made JAB-3312 the first SHP2 inhibitor to enter the phase-3 clinical study globally. The approved clinical study in China is designed to evaluate the efficacy and safety of JAB-3312 in combination with the company's other investigational drug candidate KRAS G12C inhibitor glecirasib, for treating first-line non-small cell lung cancer patients with KRAS G12C mutations. The control arm is the current standard treatment for first-line non-small cell lung cancer, which is the combination therapy of PD-1 antibody and chemotherapy. |
English singer Tom Grennan promises 'big risks' with daring new album ahead of Australian tourFive Rohingya found dead after Arakan Army arrest — Radio Free AsiaHow RFK Jr's wellHavertz scores 2 as Arsenal routs Chelsea 5Vietnam should ask Cambodia to delay canal project: experts — Radio Free AsiaSolomon Islands PM Sogavare commands largest bloc in Parliament after election — Radio Free AsiaThailand warns Myanmar’s rivals against using its soil for harm: ministers — Radio Free AsiaCheyenne Tozzi flaunts her incredible physique in a oneChanning Tatum transforms into tech billionaire in Blink Twice trailerGerman far